Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trialAlexander M.M. Eggermont, Caroline Robert, Matteo S. Carlino et al.|European Journal of Cancer|2024Cited by 84
Sequencing of Checkpoint or BRAF/MEK Inhibitors on Brain Metastases in MelanomaPaolo A. Ascierto, Vanna Chiarion‐Sileni, Mario Mandalà et al.|NEJM Evidence|2024Cited by 13
Combined immunotherapy with nivolumab and ipilimumab with and without sequential or concomitant stereotactic radiotherapy in patients with melanoma brain metastasis: An international retrospective studyMario Mandalà, Paolo A. Ascierto, Teresa Amaral et al.|European Journal of Cancer|2025Cited by 7
Accuracy of Histology and Malignancy Grade Between Preoperative Biopsy and Surgical Specimens in Primary Retroperitoneal Sarcoma. A Study From the Prospective Retroperitoneal Sarcoma Registry (RESAR)Alessandra Borghi, on behalf of the Transatlantic Australasian Retroperitoneal Sarcoma Working Group, M. Fiore et al.|Annals of Surgery|2025Cited by 2
Management of multifocal and metastatic retroperitoneal sarcoma: an updated consensus approach from the transatlantic australasian retroperitoneal sarcoma working group (TARPSWG)Chiara Fabbroni, William W. Tseng, Edward.W. Johnston et al.|Cancer Treatment Reviews|2026Cited by 0